SLN.US Silence Therapeutics PLC

Healthcare Biotechnology USA Stocks
19.80 USD
Close of Nov 18, 2026
4.19 19.87
Market cap
USD 1.23B
P/E
-
P/B
5.73x
ROE
-24.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is SLN.US undervalued?

Graham number

The Graham number of Silence Therapeutics PLC cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Silence Therapeutics PLC fundamental analysis

No fundamental analysis for Silence Therapeutics PLC yet.

Silence Therapeutics PLC stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Silence Therapeutics PLC

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease…

Full company profile